POMDOCTOR LIMITED Announces First Half of Fiscal 2025 Unaudited Financial Results

GUANGZHOU, China, Dec. 3, 2025 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced its unaudited financial results for the six months ended June 30, 2025.

Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented: "The first half of fiscal year 2025 reflected our deliberate and disciplined efforts to balance business expansion with operational rigor. Despite a challenging macroeconomic environment and intensified market competition, we strived to strengthen our market coverage and penetration, while optimizing and diversifying our revenue streams through the vigorous promotion of our internet-hospital services and online sales. During the period, we continued to solidify our partner-doctor pool by offering higher service fees, and at the same time meaningfully enhanced our collaboration with pharmaceutical manufacturers to drive online sales and adapt to China's evolving healthcare landscape. These initiatives resulted in a 16.2% increase in net revenue, highlighted by growth of 83.2% in our online-pharmacy businesses.

At the same time, we maintained strict cost controls and operational discipline, sustaining a stable gross profit margin of 16.2%. Gross profit increased 16.3% year over year, despite higher sales and marketing expenses, a larger contribution from lower-margin pharmacy products, and continued investments in customer acquisition. We prioritized retaining doctor resources while prudently reducing advertising spending, reinforcing the foundation for sustainable growth under a stable pharmaceutical supply chain.

Notably, our successful initial public offering (IPO) in October provided us with additional capital resources and expanded opportunities for future growth, further enriching our strategic options and strengthening our execution capabilities. Looking ahead, we are confident in our ability to continue improving operational performance and creating long-term value for our shareholders."

First Half of Fiscal 2025 Financial Summary

Unaudited Financial Results for the First Half of Fiscal 2025

Financial Condition

Exchange Rate Information

This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB7.1636 to US$1.00, the rate set forth in the H.10 statistical release of the U.S. Federal Reserve Board on June 30, 2025.

Recent Development

On October 9, 2025, the Company completed its initial public offering (the "Offering") of 5,000,004 American Depositary Shares ("ADSs") at a public offering price of US$4.00 per ADS. On October 10, 2025, the underwriter of the Offering fully exercised its over-allotment option to purchase an additional 750,000 American Depositary Shares of the Company at the public offering price of US$4.00 per share. The gross proceeds were US$23,000,016 from the Offering, before deducting underwriting discounts and commissions, and other expenses. The Company's ADSs began trading on the Nasdaq Global Market on October 8, 2025 under the ticker symbol "POM."

About POMDOCTOR LIMITED

POMDOCTOR LIMITED is a leading online medical services platform for chronic diseases in China, ranking sixth on China's Internet hospital market based on the number of contracted doctors in 2022, according to Frost & Sullivan. Focusing on chronic disease management and pharmaceutical services, the Company offers a one-stop platform for medical services, organically connecting patients with doctors and pharmaceutical products. The Company's operations primarily include Internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. Through this model, POMDOCTOR aims to enhance the efficiency and transparency of the healthcare value chain. The Company's mission is to provide effective prevention and treatment solutions to alleviate patients' sufferings from illnesses. Its vision is to become the most trustworthy medical and healthcare services platform. For more information, please visit the Company's website: http://ir.7shiliu.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC.

For more information, please contact:

POMDOCTOR LIMITED

Investor Relations Department

Email: [email protected]

Ascent Investor Relations LLC

Tina Xiao

Phone: +1-646-932-7242

Email: [email protected]

POMDOCTOR LIMITED

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

December 31,

2024

June 30,

2025

June 30,

2025

RMB

US$

Assets

Current assets:

Cash and cash equivalents (including amounts of the consolidated VIEs of

RMB7,596,708 and RMB5,579,802 (US$778,910) as of December 31,

2024 and June 30, 2025, respectively)

7,651,695

5,746,989

802,249

Accounts receivable, net (including amounts of the consolidated VIEs of

RMB8,374,608 and RMB6,128,066 (US$855,445) as of December 31,

2024 and June 30, 2025, respectively)

8,374,608

6,128,066

855,445

Accounts receivable – a related party (including amounts of the

consolidated VIEs of RMB424,259 and RMB584,802 (US$81,635) as

of December 31, 2024 and June 30, 2025, respectively)

424,259

584,802

81,635

Amount due from related parties (including amounts of the consolidated

VIEs of RMB6,070,945 and RMB9,643,039 (US$1,346,117) as of

December 31, 2024 and June 30, 2025, respectively)

5,632,987

7,418,671

1,035,607

Inventories (including amounts of the consolidated VIEs of

RMB9,165,973 and RMB6,447,637 (US$900,055) as of December 31,

2024 and June 30, 2025, respectively)

9,165,973

6,447,637

900,055

Other receivables, net (including amounts of the consolidated VIEs of

RMB5,318,724 and RMB5,231,722 (US$730,319) as of December 31,

2024 and June 30, 2025, respectively)

5,318,724

5,231,722

730,319

Advances to suppliers (including amounts of the consolidated VIEs of

RMB929,167 and RMB2,921,966 (US$407,891) as of December 31,

2024 and June 30, 2025, respectively)

929,167

2,921,966

407,891

Total current assets

37,497,413

34,479,853

4,813,201

Non-current assets:

Property and equipment, net (including amounts of the consolidated VIEs

of RMB461,362 and RMB394,107 (US$55,015) as of December 31,

2024 and June 30, 2025, respectively)

461,362

394,107

55,015

Other non-current assets (including amounts of the consolidated VIEs of

RMB831,132 and RMB1,307,832 (US$182,566) as of December 31,

2024 and June 30, 2025, respectively)

831,132

1,307,832

182,566

Deferred offering costs (including amounts of the consolidated VIEs of

RMB7,437,679 and RMB6,007,339 (US$838,592) as of December 31,

2024 and June 30, 2025, respectively)

7,437,679

7,690,157

1,073,505

Total non-current assets

8,730,173

9,392,096

1,311,086

Total assets

46,227,586

43,871,949

6,124,287

POMDOCTOR LIMITED

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS — (Continued)

December 31,

2024

June 30,

2025

June 30,

2025

RMB

US$

Liabilities

Current liabilities:

Accounts payable (including amounts of the consolidated VIEs of

RMB25,320,486 and RMB25,164,804 (US$3,512,871) as of December

31, 2024 and June 30, 2025, respectively)

25,320,486

25,164,804

3,512,871

Accounts payable – a related party (including amounts of the consolidated

VIEs of RMB25,891 and RMB13,711 (US$1,914) as of December 31,

2024 and June 30, 2025, respectively)

25,891

13,711

1,914

Short-term bank loans (including amounts of the consolidated VIEs of

RMB34,958,333 and RMB34,708,333 (US$4,845,096) as of December

31, 2024 and June 30, 2025, respectively)

34,958,333

34,708,333

4,845,096

Long-term bank loans, current (including amounts of the consolidated

VIEs of RMB300,000 and RMB2,400,000 (US$335,027) as of

December 31, 2024 and June 30, 2025, respectively)

300,000

2,400,000

335,027

Long-term loans, current (including amounts of the consolidated VIEs of

RMB10,000,000 and RMB10,000,000 (US$1,395,946) as of December

31, 2024 and June 30, 2025, respectively)

10,000,000

1,395,946

Long-term loans from third parties, current (including amounts of the

consolidated VIEs of RMB2,320,082 and RMB2,295,082

(US$320,381) as of December 31, 2024 and June 30, 2025,

respectively)

2,320,082

2,295,082

320,381

Salary and welfare payable (including amounts of the consolidated VIEs

of RMB15,375,537 and RMB15,543,259 (US$2,169,755) as of

December 31, 2024 and June 30, 2025, respectively)

15,375,537

15,543,259

2,169,755

Advance from customers (including amounts of the consolidated VIEs of

RMB1,756,046 and RMB942,724 (US$131,599) as of December 31,

2024 and June 30, 2025, respectively)

1,756,046

942,724

131,599

Value added tax ("VAT") and other tax payable (including amounts of the

consolidated VIEs of RMB815,462 and RMB998,295 (US$139,357) as

of December 31, 2024 and June 30, 2025, respectively)

815,462

998,295

139,357

Other payables (including amounts of the consolidated VIEs of

RMB12,888,550 and RMB10,543,238 (US$1,471,777) as of December

31, 2024 and June 30, 2025, respectively)

12,888,750

10,543,438

1,471,806

Accrued liabilities (including amounts of the consolidated VIEs of

RMB9,712,966 and RMB11,564,144 (US$1,614,292) as of December

31, 2024 and June 30, 2025, respectively)

9,712,966

11,564,144

1,614,292

Short-term loans from third parties (including amounts of the consolidated

VIEs of RMB11,551,614 and RMB7,194,342 (US$1,004,291) as of

December 31, 2024 and June 30, 2025, respectively)

11,551,614

7,194,342

1,004,291

Loans from related parties, current (including amounts of the consolidated

VIEs of RMB13,821,875 and RMB33,194,670 (US$4,633,797) as of

December 31, 2024 and June 30, 2025, respectively)

13,821,875

33,194,670

4,633,797

Amount due to related parties (including amounts of the consolidated

VIEs of RMB36,829,010 and RMB42,403,073 (US$5,919,241) as of

December 31, 2024 and June 30, 2025, respectively)

36,829,010

42,403,073

5,919,241

POMDOCTOR LIMITED

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS — (Continued)

December 31,

2024

June 30,

2025

June 30,

2025

RMB

US$

Operating lease liabilities, current (including amounts of the

consolidated VIEs of RMB1,388,863 and RMB1,790,319

(US$249,919) as of December 31, 2024 and June 30, 2025,

respectively)

1,388,863

1,790,319

249,919

Other current liabilities (including amounts of the consolidated

VIEs of RMB2,080,556 and RMB237,580 (US$33,165) as of

December 31, 2024 and June 30, 2025, respectively)

2,080,556

237,580

33,165

Total current liabilities

179,145,471

198,993,774

27,778,457

Long-term bank loans, noncurrent (including amounts of the

consolidated VIEs of RMB8,400,000 and RMB5,700,000

(US$795,689) as of December 31, 2024 and June 30, 2025,

respectively)

8,400,000

5,700,000

795,689

Loans from related parties, noncurrent (including amounts of the

consolidated VIEs of RMB356,690,859 and RMB356,390,859

(US$49,750,246) as of December 31, 2024 and June 30, 2025,

respectively)

356,690,859

356,390,859

49,750,246

Operating lease liabilities, noncurrent (including amounts of the

consolidated VIEs of RMB1,672,218 and RMB2,346,664

(US$327,582) as of December 31, 2024 and June 30, 2025,

respectively)

1,672,218

2,346,664

327,582

Total non-current liabilities

366,763,077

364,437,523

50,873,517

Total liabilities

545,908,548

563,431,297

78,651,974

Commitments and contingencies

—

Mezzanine equity

Convertible redeemable preferred shares (US$0.0001 par value;

12,597,228 shares authorized, issued and outstanding as of

December 31, 2024 and June 30, 2025)

1,595,051,558

1,642,498,390

229,283,934

Redeemable non-controlling interests

168,671,234

173,630,137

24,237,833

Total mezzanine equity

1,763,722,792

1,816,128,527

253,521,767

Equity (deficit)

Class A ordinary shares (US$0.0001 par value; 485,360,730

shares authorized, 4,268,156 shares issued and outstanding as of

December 31, 2024 and June 30, 2025)

2,988

417

Class B Ordinary shares (US$0.0001 par value; 2,042,042 shares

authorized and outstanding as of December 31, 2024 and

June 30, 2025, respectively)

1,408

197

Subscription receivable

(1,608)

(224)

Accumulated deficit

(2,263,419,477)

(2,335,709,744)

(326,052,508)

Accumulated other comprehensive (loss) income

(5,231)

1,875

262

Total Pomdoctor Limited's shareholders' deficit

(2,263,421,920)

(2,335,705,081)

(326,051,856)

Noncontrolling interests

18,166

17,206

2,402

Total deficit

(2,263,403,754)

(2,335,687,875)

(326,049,454)

Total liabilities, mezzanine equity and deficit

46,227,586

43,871,949

6,124,287

POMDOCTOR LIMITED

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND

COMPREHENSIVE LOSS

For Six Months Ended June 30,

2024

2025

RMB

US$

Net revenues – third parties

149,266,587

174,283,295

24,329,010

Net revenues – a related party

897,822

186,556

26,042

Net revenues

150,164,409

174,469,851

24,355,052

Cost of revenues

125,823,734

146,152,450

20,402,095

Gross profit

24,340,675

28,317,401

3,952,957

Operating expenses:

Sales and marketing expenses

24,884,898

27,761,736

3,875,389

General and administrative expenses

6,835,897

10,494,487

1,464,974

Research and development expenses

1,507,847

1,479,909

206,587

Impairment loss on long-lived assets

17,861

2,041,299

284,954

Total operating expenses

33,246,503

41,777,431

5,831,904

Loss from operations

(8,905,828)

(13,460,030)

(1,878,947)

Other income (expenses):

Other income

1,078,270

28,027

3,912

Other expense

(33,681)

(130,291)

(18,188)

Interest expense

(6,179,172)

(6,471,198)

(903,344)

Government grants

13,858

148,000

20,660

Total other expense, net

(5,120,725)

(6,425,462)

(896,960)

Loss before income tax

(14,026,553)

(19,885,492)

(2,775,907)

Income tax expense

—

Net loss

(14,026,553)

(19,885,492)

(2,775,907)

Accretion to redemption value of mezzanine equity

(52,695,272)

(52,405,735)

(7,315,559)

Less: Net income (loss) attributable to noncontrolling interests

27,639

(960)

(134)

Net loss attributable to the Pomdoctor Limited's ordinary

shareholders

(66,749,464)

(72,290,267)

(10,091,332)

Net loss

(14,026,553)

(19,885,492)

(2,775,907)

Other comprehensive (loss) income:

Total other comprehensive (loss) income

(3,970)

7,106

992

Total comprehensive loss

(14,030,523)

(19,878,386)

(2,774,915)

Accretion to redemption value of mezzanine equity

(52,695,272)

(52,405,735)

(7,315,559)

Less: comprehensive income (loss) attributable to noncontrolling

interests

27,639

(960)

(134)

Comprehensive loss attributable to the Pomdoctor Limited's

ordinary shareholders

(66,753,434)

(72,283,161)

(10,090,340)

Loss per share

Basic and diluted

(10.58)

(11.45)

(1.60)

Weighted average number of ordinary shares outstanding*

Basic and diluted

6,310,198

* Ordinary shares and share data have been retroactively restated to give effect to the nominal share issuance for

the Reorganization completed on August 8, 2024

POMDOCTOR LIMITED

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For Six Months Ended June 30,

2024

2025

RMB

US$

Net cash used in operating activities

(10,631,121)

(14,987,658)

(2,092,195)

Cash flows from investing activities:

Payment for purchase of property and equipment

(17,862)

(2,200)

(307)

Payment for long-term investment

—

(510,000)

(71,193)

Net cash used in investing activities

(17,862)

(512,200)

(71,500)

Cash flows from financing activities:

Loans from related parties

11,219,986

24,750,310

3,455,010

Repayment to related parties

(14,436,941)

(5,677,514)

(792,550)

Proceeds from short-term bank loans

37,000,000

29,000,000

4,048,244

Repayment of short-term bank loans

(19,300,000)

(29,250,000)

(4,083,143)

Repayment of long-term bank loans

(54,628)

(600,000)

(83,757)

Loans from third parties

8,759,366

1,600,000

223,351

Repayment to third parties

(4,968,912)

(5,982,272)

(835,093)

Payment for deferred offering cost

(1,656,745)

(252,478)

(35,245)

Net cash provided by financing activities

16,562,126

13,588,046

1,896,817

Effect of exchange rate changes

(3,970)

7,106

992

Net increase (decrease) in cash and cash equivalents and restricted

cash

5,909,173

(1,904,706)

(265,886)

Cash and cash equivalents and restricted cash at beginning of the

period

6,805,099

7,651,695

1,068,135

POMDOCTOR LIMITED

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS — (Continued)

For Six Months Ended June 30,

2024

2025

RMB

US$

Including:

Cash and cash equivalents at beginning of the period

6,717,031

7,651,695

1,068,135

Restricted cash at beginning of the period

88,068

—

Cash and cash equivalents and restricted cash at end of the period

12,714,272

5,746,989

802,249

Including:

Cash and cash equivalents at end of the period

12,714,272

5,746,989

802,249

Supplemental disclosures of cash flows information:

Cash paid for interest expense

1,130,609

2,382,125

332,532

Supplemental disclosure of noncash investing and financing activities:

Operating lease right-of-use assets obtained in exchange for new operating

lease liabilities

—

2,039,099

284,647

SOURCE POMDOCTOR LIMITED